• Resources
  • Blog
  • Journalists
  • Log In
  • Sign Up
  • Data Privacy
  • Send a Release
Cision PR Newswire: news distribution, targeting and monitoring home
  • News
  • Products
  • Contact

 

When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • Sponsored Placement
  • All Products
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • All Products
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR

ORIG3N Opens Regenerative Medicine Laboratory and Expanded Headquarters In Boston's Innovation District

Advancing the future of medicine by providing the world's largest biorepository of iPS cells;

Mayor Walsh Proclaims April 26th "Future of Medicine Day" for the City of Boston


News provided by

ORIG3N, Inc.

Apr 26, 2016, 01:44 ET

Share this article

Share this article


BOSTON, April 26, 2016 /PRNewswire/ -- ORIG3N, Inc., a pioneer in the field of regenerative medicine, today announced the formal opening of its new headquarters and laboratory in Boston's Seaport District, at 27 Drydock Avenue within the Innovation and Design Building. ORIG3N's new expanded facility will provide state-of-the-art functionality to sustain collaborative research programs that support ORIG3N's cellular models called LifeSystems™, as well as the company's product development and commercial activities.

Mayor Martin J. Walsh donated a blood sample for Boston-based ORIG3N, which is building the world's largest crowdsourced biorepository of induced pluripotent stem cells, called LIfeCapsule. A half teaspoon of donated blood can be grown into different cell types, including neurons, heart cells and liver cells.
Mayor Martin J. Walsh donated a blood sample for Boston-based ORIG3N, which is building the world's largest crowdsourced biorepository of induced pluripotent stem cells, called LIfeCapsule. A half teaspoon of donated blood can be grown into different cell types, including neurons, heart cells and liver cells.
Mayor Martin J. Walsh viewed the contents of ORIG3N's LifeCapsule, the world's largest biorepository of induced pluripotent stem cells (iPSCs), during a lab tour with Marcie Glicksman, VP of Biology at ORIG3N. ORIG3N is the only biotechnology company that is crowdsourcing blood samples to understand the cellular and molecular foundations of disease. ORIG3N's new facility will help accelerate the next stage of evolution with iPSC technology.
Mayor Martin J. Walsh viewed the contents of ORIG3N's LifeCapsule, the world's largest biorepository of induced pluripotent stem cells (iPSCs), during a lab tour with Marcie Glicksman, VP of Biology at ORIG3N. ORIG3N is the only biotechnology company that is crowdsourcing blood samples to understand the cellular and molecular foundations of disease. ORIG3N's new facility will help accelerate the next stage of evolution with iPSC technology.
Boston Mayor Martin J. Walsh viewed beating heart cells created with induced pluripotent stem cell technology during a tour of ORIG3N's new regenerative medicine lab.
Boston Mayor Martin J. Walsh viewed beating heart cells created with induced pluripotent stem cell technology during a tour of ORIG3N's new regenerative medicine lab.
Mayor Martin J. Walsh donated a blood sample for Boston-based ORIG3N, which is building the world's largest crowdsourced biorepository of induced pluripotent stem cells, called LIfeCapsule. A half teaspoon of donated blood can be grown into different cell types, including neurons, heart cells and liver cells. Mayor Martin J. Walsh viewed the contents of ORIG3N's LifeCapsule, the world's largest biorepository of induced pluripotent stem cells (iPSCs), during a lab tour with Marcie Glicksman, VP of Biology at ORIG3N. ORIG3N is the only biotechnology company that is crowdsourcing blood samples to understand the cellular and molecular foundations of disease. ORIG3N's new facility will help accelerate the next stage of evolution with iPSC technology. Boston Mayor Martin J. Walsh viewed beating heart cells created with induced pluripotent stem cell technology during a tour of ORIG3N's new regenerative medicine lab.

Founded in 2014 by serial entrepreneurs Robin Y. Smith, CEO and Kate Blanchard, COO, ORIG3N uses iPSC technology to accelerate the future of medicine, including the pace of drug development, to overcome the trial-and-error approach common today. ORIG3N is the only biotechnology company that is crowdsourcing blood samples creating a new approach to the understanding and treatment of a variety of diseases.

ORIG3N builds and maintains the world's largest crowdsourced biorepository of induced pluripotent stem cells (iPSCs) called LifeCapsule™. The new facility will help accelerate the next stage of evolution with iPSC technology.

"Regenerative medicine is at the same stage today as the Internet was in 1993.  We are on the verge of seeing huge advances in this technology and as part of our mission we are making large and diverse patient cohorts available to researchers while at the same time educating patients on what this technology is," said Smith, in addressing an audience that included government officials and representatives from the biotech and life sciences community. "Being in Boston enables our organization to bring our technology to the epicenter of biotech research in the US."

"The foundation for the regenerative medicine revolution requires unhindered access to patient samples," adds Blanchard. "LifeCapsule has grown exponentially by directly engaging with consumers and patients worldwide.  The remarkable growth of LifeCapsule has given ORIG3N the unique ability to create a living snapshot of humanity."

In attending the opening, Mayor Martin J. Walsh noted, "ORIG3N is a great fit for the Innovation District and our city's biotechnology and life sciences community, and we are proud to welcome them to Boston. Their work in studying rare, genetically-inherited diseases will have a huge impact on the future of medicine. ORIG3N's future is bright as they continue to expand and grow their partnerships, and we are excited that they see Boston as the best place to succeed."

About ORIG3N, Inc.
ORIG3N is leading a transformation of the understanding and treatment of rare, genetically-inherited diseases. We've established the world's largest crowdsourced cell repository to better understand the cellular and molecular foundations of disease. The cells are ever-renewing and give rise to a living database of humanity we call LifeCapsule. Thousands of people have already contributed to advancing the future of healthcare—and to safeguarding their own future health. The founders are serial entrepreneurs whose previous venture, ArtusLabs, was acquired by PerkinElmer in 2011.

For more information, visit www.orig3n.com.

Contact: Rebecca LeWinter, (973) 280-7582, [email protected]

Photo - http://photos.prnewswire.com/prnh/20160426/360063
Photo - http://photos.prnewswire.com/prnh/20160426/360064 
Photo - http://photos.prnewswire.com/prnh/20160426/360066 

SOURCE ORIG3N, Inc.

Related Links

http://www.orig3n.com

Modal title

Contact Cision

  • Cision Distribution 888-776-0942
    from 8 AM - 9 PM ET

  • Chat with an Expert
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • Cision Communication Cloud®
  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • For Small Business
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • COVID-19 Resources
  • Accessibility Statement
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom

My Services

  • All New Releases
  • Online Member Center
  • ProfNet

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2023 Cision US Inc.